Table II.

Univariate and multivariate analysis of risk factors for overall survival.

	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	P-value	HR	95% CI	P-value
Sex (male/female)	1.026	0.617–1.706	0.922
Age (<45/≥45 years)	0.850	0.506–1.428	0.540
TNM stage (I–II/III–IV)	0.474	0.245–0.918	0.027a	1.003	0.462–2.176	0.995
Tumor diameter (≤5/>5 cm)	0.460	0.260–0.814	0.008b	0.728	0.348–1.527	0.402
R0 (R0/R1)	0.515	0.310–0.857	0.011a	0.739	0.403–1.354	0.327
Differentiation (low)	1.000
Differentiation (moderate)	2.193	0.873–5.510	0.095
Differentiation (high)	1.349	0.411–4.423	0.622
Lymph node metastasis (positive/negative)	2.865	1.658–4.952	<0.001c	0.919	0.472–1.788	0.803
Intrahepatic metastasis (positive/negative)	9.266	4.863–17.657	<0.001c	2.826	1.288–6.201	0.010a
Multiplicity (positive/negative)	6.125	3.482–10.774	<0.001c	4.004	1.923–8.336	<0.001c
Vascular invasion (positive/negative)	5.875	3.252–10.614	<0.001c	3.187	1.516–6.701	0.002b
Pyruvate kinase M2 expression (high/low)	1.984	1.177–3.344	0.010a	1.364	1.048–2.948	0.007b
Diabetes mellitus (yes/no)	2.152	1.255–3.691	0.005b	1.989	1.084–3.650	0.026a
Total bilirubin (>34/≤34 µmol/l)	0.780	0.414–1.470	0.442
Alanine aminotransferase (>100/≤100 IU/l)	0.940	0.477–1.855	0.859
Prothrombin time (>14/≤14 sec)	1.533	0.556–4.232	0.409
Albumin (>35/≤35 g/l)	0.672	0.340–1.326	0.252
Aspartate aminotransferase (>100/≤100 IU/l)	1.310	0.731–2.348	0.365

^aP<0.05

^bP<0.01

^cP<0.001. HR, hazard ratio; IU, international unit.